Heart drug trial offers hope for millions with long COVID
NCT ID NCT06907251
Summary
This study is testing whether dapagliflozin, a medication typically used for diabetes and heart conditions, can help people with long COVID. Researchers will give 192 participants either the real drug or a placebo pill daily for one year to see if it improves their quality of life and reduces health risks. The goal is to see if this existing medication can help control the ongoing symptoms and complications of long COVID.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Ottawa Heart Institute
Ottawa, Ontario, K1Y 4W7, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.